^
Association details:
| Biomarker: | EGFR S492R |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Excerpt:
These experiments clearly showed that EGFR mutations were not permissive for binding to cetuximab, providing functional evidence of their role in driving acquired resistance to this drug. So far, four mutations in the ECD of EGFR have been identified to drive resistance to approved anti-EGFR mAb in patients: S492R, R451C, K467T after cetuximab and G465R after panitumumab failure.
DOI:
10.1158/1078-0432.CCR-15-2400
